Prader-Willi Syndrome | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Aug 2, 2018--Technavio has announced their latest analysis report on drug pipeline for . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Prader-Willi syndrome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180802005900/en/
Technavio has published a new report on the drug development pipeline for Prader-Willi syndrome, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Prader-Willi syndrome: Market overview
Prader-Willi syndrome is a disorder that is caused due to loss of active genes in a specific region of chromosome 15. The part of the brain that controls feelings of fullness does not work properly for people who have PWS. Fluorescence in situ hybridization (FISH) test identifies deleted genes in the chromosomes of people with PWS. DNA methylation testing is another preferred diagnostic method for PWS genetic testing. This testing identifies abnormal, parent related imprinting in the region of chromosome 15, which is responsible for the development of PWS.
According to a senior market research analyst at Technavio, “As per the data published by the EMA based on the Committee for Orphan Medicinal Products in October 2017, PWS affected approximately 0.4 people in 10,000 people in the EU.”
Prader-Willi syndrome: Segmentation analysis
This pipeline analysis report segments the Prader-Willi syndrome market based on therapies employed (monotherapy and combination therapy), RoA (oral, subcutaneous, intranasal, and parenteral), therapeutic modality (small molecule, peptide, lipid, and protein), targets (somatotropin receptor, oxytocin receptor, and others), MoA (somatotropin receptor agonist and oxytocin receptor agonist), geographical segmentation (US, China, South Korea, Czech Republic, and Canada) and recruitment status (completed, planned, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapies employed, close to 87% of the molecules that are being investigated for the treatment of Prader-Willi syndrome is monotherapy. Monotherapy uses a single drug to treat a particular disorder.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005900/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH GENETICS PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/02/2018 03:58 PM/DISC: 08/02/2018 03:58 PM